Taimei Technology (02576.HK)?is a digital-intelligent operation platform for the life sciences industry, with business coverage spanning pharmaceutical R&D, pharmacovigilance, and marketing. Leveraging full-stack AI capabilities and digital infrastructure, the company has independently developed over 40 SaaS products and services. Its?"Wiz" AI platform?integrates advanced AI large models and dynamic learning algorithms to deliver?trustworthy, applicable, and perceptible AI agents?as well as?end-to-end AI-powered digital-intelligent solutions, enhancing overall pharmaceutical R&D efficiency and post-market commercial performance. Rooted in China and expanding globally, Taimei Technology is headquartered in China with branches in Singapore and the U.S., extending its services to major pharmaceutical markets worldwide. To date, the company has served?over 1,400 pharmaceutical companies and CROs. It has been recognized as a?National High-Tech Enterprise, a?National "Little Giant" Specialized and Sophisticated SME, and a?Zhejiang Provincial Technology "Little Giant" Enterprise, among other provincial and ministerial honors. Its main products hold a?leading market share in China. Taimei Technology is dedicated to its mission of "Making Health Accessible through the Power of Digitalization." In pursuit of this mission, we are building the?next-generation digital-intelligent infrastructure?for the future of the pharmaceutical industry. By driving transformation with intelligence and breaking conventions through innovation, the company strives to?make drug R&D more efficient, medication safer for patients, and effective therapies more accessible while reducing healthcare burdens